ENSG Ensign Group, Inc
Updated
Healthcare · Services-Skilled Nursing Care Facilities
Ensign Group, Inc (ENSG) is a healthcare company in the Services-Skilled Nursing Care Facilities industry, with a market capitalization of $10.0 billion. Shares last traded at $172.03, 20.8% below their 52-week high. Over the past year the stock is up 0.3%. ENSG trades at a price-to-earnings ratio of 26.48, below the Healthcare median of 27.46. Net profit margin is 6.9%, above the peer median of -1.5%. Revenue grew 18.8% year over year. The shares yield 0.1% in dividends.
Performance
Chart
Full chart →Daily candles · volume · SMA(20)/SMA(50) · Databento EQUS.MINI.
Technicals
Financials
Latest reported annual period ending 2026-06-30 · SEC EDGAR/XBRL.
ENSG Dividend History
| Fiscal year end | Total dividends paid | Per share* | Payout ratio |
|---|---|---|---|
| 2025-12-31 | $14M | $0.24 | 4% |
| 2024-12-31 | $14M | $0.23 | 5% |
| 2023-12-31 | $13M | $0.22 | 6% |
| 2022-12-31 | $12M | $0.21 | 5% |
| 2021-12-31 | $12M | $0.20 | 6% |
| 2020-12-31 | $11M | $0.19 | 6% |
| 2019-12-31 | $10M | $0.18 | 9% |
| 2018-12-31 | $9M | $0.17 | 10% |
| 2017-12-31 | $9M | $0.17 | 22% |
| 2016-12-31 | $8M | $0.16 | 16% |
| 2015-12-31 | $7M | $0.14 | 14% |
| 2014-12-31 | $6M | $0.14 | 18% |
*Per share derived as total dividends paid ÷ weighted diluted shares (SEC EDGAR/XBRL annual cash-flow facts). Reported history — not a forecast of future dividends.
Compare payers on the highest-dividend-yield screener.
Recent earnings
| Period | EPS (diluted) | Reported |
|---|---|---|
| Q2 2026 | $3.35 | 2026-07-27 |
| Q1 2026 | $1.67 | 2026-04-30 |
| FY 2025 | $5.84 | 2026-02-04 |
| Q3 2025 | $4.23 | 2025-11-03 |
| Q2 2026 | $2.81 | 2026-07-27 |
| Q1 2026 | $1.37 | 2026-04-30 |
Healthcare peers
ENSG vs 14 sector peers (Healthcare), by market cap. Updated
| LLY | Lilly (Eli) | $1.09T | 40.86 | 13.70 | 33.5% | -0.02% |
| JNJ | Johnson & Johnson | $670.6B | 31.88 | 6.85 | 21.5% | +1.04% |
| ONC | Beone Medicines Ltd. | $535.9B | 817.25 | 87.43 | 10.7% | +0.23% |
| ABBV | AbbVie | $459.8B | 72.87 | 7.14 | 9.8% | -0.57% |
| MRK | Merck | $375.8B | 118.44 | 5.65 | 4.8% | +0.44% |
| AMGN | Amgen | $240.1B | 27.47 | 6.30 | 23.0% | +0.31% |
| TMO | Thermo Fisher Scientific | $228.7B | 32.82 | 4.94 | 15.0% | +1.66% |
| KLAC | KLA Corporation | $225.9B | 46.76 | 16.64 | 35.6% | +0.37% |
| ABT | Abbott Laboratories | $189.5B | 30.20 | 4.20 | 13.9% | -1.50% |
| GILD | Gilead Sciences | $187.5B | -57.87 | 6.16 | -10.6% | +1.09% |
| PFE | Pfizer | $164.2B | 37.91 | 2.58 | 6.8% | -0.76% |
| DHR | Danaher Corporation | $148.3B | 37.05 | 5.91 | 15.9% | +0.49% |
| VRTX | Vertex Pharmaceuticals | $141.5B | 32.11 | 11.24 | 35.0% | +0.24% |
| BMY | Bristol Myers Squibb | $139.1B | 14.98 | 2.83 | 18.9% | +0.62% |
Source: SEC EDGAR (fundamentals/EPS/dividends) · Databento EQUS.MINI (prices) · market cap & yield computed by tradmap. Informational only — not financial advice.